Cancer Archives

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2017

German Pharma Enters the Clinic with Solid Tumor Treatment

A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […]

September 28, 2017 - 2 minutesmins - By Alex Dale

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

News and Trends 26 Sep 2017

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […]

September 26, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 Sep 2017

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […]

September 25, 2017 - 1 minutemin - By Alex Dale

News and Trends 21 Sep 2017

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Merck and Pfizer’s new immunotherapy, avelumab, has been approved by the European Commission to treat metastatic Merkel cell carcinoma, an aggressive form of skin cancer. The approval is based on data from a Phase II study, JAVELIN Merkel 200, where subjects responded well to treatment for a sustained period of time. Earlier this year, Avelumab was […]

September 21, 2017 - 3 minutesmins - By Alex Dale

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […]

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 13 Sep 2017

A Swedish-Spanish Team Takes on a New Immuno-Oncology Target

Alligator Bioscience will collaborate with the University of Navarra, Spain, to study the potential of CD137 as a target for new cancer immunotherapies. Alligator Bioscience, based in Lund, Sweden, has teamed up with Prof. Ignacio Melero at the Center for Applied Medical Research (CIMA) at the University of Navarra to study the biological effects of activating […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Sep 2017

Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer

Genenta Science has raised $8M (€7M) in the Series B fundraising round to continue investigating its use of hematopoietic stem cells to treat cancer. Based in Milan, Genenta can add €7M to the €10M secured in Series A of fundraising. Italian, British and Swiss private investors led the investment, and it will allow the biotech to start a second […]

September 13, 2017 - 2 minutesmins - By Alex Dale

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

German Pharma Enters the Clinic with Solid Tumor Treatment

What are Alphabodies and How Do They Drug the Undruggable?

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

A Swedish-Spanish Team Takes on a New Immuno-Oncology Target

Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!